Vis enkel innførsel

dc.contributor.authorDublang, Leire
dc.contributor.authorUnderhaug, Jarl
dc.contributor.authorFlydal, Marte Innselset
dc.contributor.authorVelasco-Carneros, Lorea
dc.contributor.authorMaréchal, Jean-Didier
dc.contributor.authorMoro, Fernando
dc.contributor.authorBoyano, Maria Dolores
dc.contributor.authorMartinez, Aurora
dc.contributor.authorMuga, Arturo
dc.date.accessioned2022-01-20T08:51:09Z
dc.date.available2022-01-20T08:51:09Z
dc.date.created2021-12-15T09:20:38Z
dc.date.issued2021
dc.identifier.issn2072-6694
dc.identifier.urihttps://hdl.handle.net/11250/2838404
dc.description.abstractHeat shock protein (Hsp) synthesis is upregulated in a wide range of cancers to provide the appropriate environment for tumor progression. The Hsp110 and Hsp70 families have been associated to cancer cell survival and resistance to chemotherapy. In this study, we explore the strategy of drug repurposing to find new Hsp70 and Hsp110 inhibitors that display toxicity against melanoma cancer cells. We found that the hits discovered using Apg2, a human representative of the Hsp110 family, as the initial target bind also to structural regions present in members of the Hsp70 family, and therefore inhibit the remodeling activity of the Hsp70 system. One of these compounds, the spasmolytic agent pinaverium bromide used for functional gastrointestinal disorders, inhibits the intracellular chaperone activity of the Hsp70 system and elicits its cytotoxic activity specifically in two melanoma cell lines by activating apoptosis. Docking and molecular dynamics simulations indicate that this compound interacts with regions located in the nucleotide-binding domain and the linker of the chaperones, modulating their ATPase activity. Thus, repurposing of pinaverium bromide for cancer treatment appears as a promising novel therapeutic approach.en_US
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleInhibition of the Human Hsc70 System by Small Ligands as a Potential Anticancer Approachen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2021 by the authors.en_US
dc.source.articlenumber2936en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.3390/cancers13122936
dc.identifier.cristin1968629
dc.source.journalCancersen_US
dc.relation.projectNorges forskningsråd: 245922en_US
dc.relation.projectHelse Vest RHF: 912246en_US
dc.relation.projectNorges forskningsråd: 261826en_US
dc.identifier.citationCancers. 2021, 13 (12), 2936.en_US
dc.source.volume13en_US
dc.source.issue12en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal